Rules unlock access to Orphan drugs
In this issue:
Putting a fair price-tag on orphan drugs
After more than two years of negotiations, a collaboration involving Member States, the European Commission, patient representative organisations, national insurers and industry has finally published the first non-binding guidelines for evaluating and reimbursing orphan drugs. The framework is a first tentative step forward in addressing a thorny and divisive topic. How much should pharma companies be allowed to earn for treating rare diseases? And how much can insurers afford to pay?